Results 171 to 180 of about 9,558 (217)

Rilpivirine: The Key for Long-term Success

Aids Reviews, 2017
During the past 30 years of antiretroviral therapy, continuous improvements in drug discovery have provided increasingly potent and safer antivirals that have transformed HIV infection in a chronic illness, rarely fatal. Non-nucleoside reverse-transcriptase inhibitors (NNRTIs) are frequently used as part of any antiretroviral combination therapy.
openaire   +2 more sources

Rilpivirine

Drugs of the Future, 2007
null Sorbera, L.A., null Serradell, N., null Rosa, E., null Bolos, J.   +3 more
openaire   +1 more source

Dolutegravir/rilpivirine

Reactions Weekly, 2023
openaire   +1 more source

Rilpivirine

Reactions Weekly, 2017
openaire   +2 more sources

Cabotegravir/rilpivirine

Reactions Weekly
  +6 more sources

Cabotegravir/Rilpivirine: the last FDA-approved drug to treat HIV

Expert Review of Anti-Infective Therapy, 2022
Faezeh Soleimani, Arezoo asadi, Mohsen Heidary   +2 more
exaly  

Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study

Lancet, The, 2020
Edgar T Overton, Giuliano Rizzardini, Susan Swindells   +2 more
exaly  

Dolutegravir/rilpivirine

Reactions Weekly, 2018
openaire   +2 more sources

Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression

New England Journal of Medicine, 2020
Susan Swindells, Giuliano Rizzardini, Mar Masiá   +2 more
exaly  

Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection

New England Journal of Medicine, 2020
Chloe Orkin, Edgar T Overton, Christopher Bettacchi   +2 more
exaly